Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Benzoic Acid, 3-(2-(((4s)-4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl)methylamino)ethyl)-, Methyl Ester
2. Methyl 3-(2-(((4s)-4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl)(methyl)amino)ethyl)benzoate
1. 1593673-23-4
2. Msp-2017
3. (-)-msp-2017
4. Ms)-msp-2017
5. S82a18y42p
6. Methyl (s)-3-(2-((4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl)(methyl)amino)ethyl)benzoate
7. Benzoic Acid, 3-(2-(((4s)-4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl)methylamino)ethyl)- , Methyl Ester
8. Etripamil [usan:inn]
9. Unii-s82a18y42p
10. Etripamil [inn]
11. Etripamil (usan/inn)
12. Etripamil [usan]
13. Etripamil [who-dd]
14. Chembl3707312
15. Ex-a5306
16. Db12605
17. Hy-17611
18. Cs-0014689
19. D10932
20. Q27289030
21. Benzoic Acid, 3-(2-(((4s)-4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl)methylamino)ethyl)-, Methyl Ester
22. Methyl 3-[2-[[(4s)-4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-methylamino]ethyl]benzoate
| Molecular Weight | 452.6 g/mol |
|---|---|
| Molecular Formula | C27H36N2O4 |
| XLogP3 | 3.7 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 13 |
| Exact Mass | 452.26750763 g/mol |
| Monoisotopic Mass | 452.26750763 g/mol |
| Topological Polar Surface Area | 71.8 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 645 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of supraventricular arrhythmias
Calcium Channel Blockers
A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)
Drugs in Development
Details:
Etripamil, a miscellaneous product targeting voltage-gated L-type calcium channels, shows promise in treating Paroxysmal Supraventricular Tachycardia (PSVT).
Lead Product(s): Etripamil,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Cardamyst
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 12, 2025
Lead Product(s) : Etripamil,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Milestone Gets FDA Nod for CARDAMYST™ Nasal Spray for PSVT in Adults
Details : Etripamil, a miscellaneous product targeting voltage-gated L-type calcium channels, shows promise in treating Paroxysmal Supraventricular Tachycardia (PSVT).
Product Name : Cardamyst
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 12, 2025
Details:
Milestone intends to use the net proceeds to fund the clinical development and commercial launch of Cardamyst (etripamil) in its lead indication of paroxysmal supraventricular tachycardi.
Lead Product(s): Etripamil,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Cardamyst
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: TD Cowen
Deal Size: $52.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 11, 2025
Lead Product(s) : Etripamil,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : TD Cowen
Deal Size : $52.5 million
Deal Type : Public Offering
Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering
Details : Milestone intends to use the net proceeds to fund the clinical development and commercial launch of Cardamyst (etripamil) in its lead indication of paroxysmal supraventricular tachycardi.
Product Name : Cardamyst
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 11, 2025
Details:
Milestone intends to use the net proceeds to fund the clinical development and commercial launch of Cardamyst (etripamil) in its lead indication of paroxysmal supraventricular tachycardi.
Lead Product(s): Etripamil,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Cardamyst
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: TD Cowen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering July 11, 2025
Lead Product(s) : Etripamil,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : TD Cowen
Deal Size : Undisclosed
Deal Type : Public Offering
Milestone Pharmaceuticals Announces Proposed Public Offering
Details : Milestone intends to use the net proceeds to fund the clinical development and commercial launch of Cardamyst (etripamil) in its lead indication of paroxysmal supraventricular tachycardi.
Product Name : Cardamyst
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 11, 2025
Details:
Cardamyst (etripamil), a novel calcium channel blocker nasal spray, is being investigated for the management of paroxysmal supraventricular tachycardia.
Lead Product(s): Etripamil,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Cardamyst
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 28, 2025
Lead Product(s) : Etripamil,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Issues Complete Response Letter for Etripamil for PSVT
Details : Cardamyst (etripamil), a novel calcium channel blocker nasal spray, is being investigated for the management of paroxysmal supraventricular tachycardia.
Product Name : Cardamyst
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 28, 2025
Details:
Etripamil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atrial Fibrillation.
Lead Product(s): Etripamil,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 04, 2024
Lead Product(s) : Etripamil,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3
Details : Etripamil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atrial Fibrillation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 04, 2024
Details:
Cardamyst (etripamil), a novel calcium channel blocker nasal spray, is being investigated for the management of paroxysmal supraventricular tachycardia.
Lead Product(s): Etripamil,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Cardamyst
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 29, 2024
Lead Product(s) : Etripamil,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST„
Details : Cardamyst (etripamil), a novel calcium channel blocker nasal spray, is being investigated for the management of paroxysmal supraventricular tachycardia.
Product Name : Cardamyst
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 29, 2024
Details:
MSP-2017 (etripamil) is a fast-acting, intranasally administered calcium-channel blocker, which is being evaluated for the treatment of Paroxysmal Supraventricular Tachycardia.
Lead Product(s): Etripamil,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Cardamyst
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 28, 2024
Lead Product(s) : Etripamil,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Milestone Resubmits NDA for Etripamil for Paroxysmal Supraventricular Tachycardia
Details : MSP-2017 (etripamil) is a fast-acting, intranasally administered calcium-channel blocker, which is being evaluated for the treatment of Paroxysmal Supraventricular Tachycardia.
Product Name : Cardamyst
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 28, 2024
Details:
Milestone intends to use the net proceeds from the Offering to continue the development of Cardamyst (etripamil) in its lead indication of paroxysmal supraventricular tachycardia.
Lead Product(s): Etripamil,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Cardamyst
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Piper Sandler
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 29, 2024
Lead Product(s) : Etripamil,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Piper Sandler
Deal Size : $30.0 million
Deal Type : Public Offering
Milestone Pharmaceuticals Prices $30 Million Public Offering of Common Shares and Warrants
Details : Milestone intends to use the net proceeds from the Offering to continue the development of Cardamyst (etripamil) in its lead indication of paroxysmal supraventricular tachycardia.
Product Name : Cardamyst
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 29, 2024
Details:
Milestone intends to use the net proceeds from the offering to continue the development of MSP-2017 (etripamil) in its lead indication of paroxysmal supraventricular tachycardia.
Lead Product(s): Etripamil,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Cardamyst
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Piper Sandler
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering February 28, 2024
Lead Product(s) : Etripamil,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Piper Sandler
Deal Size : Undisclosed
Deal Type : Public Offering
Milestone Proposes Public Offering of Common Shares and Pre-Funded Warrants
Details : Milestone intends to use the net proceeds from the offering to continue the development of MSP-2017 (etripamil) in its lead indication of paroxysmal supraventricular tachycardia.
Product Name : Cardamyst
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 28, 2024
Details:
MSP-2017 (etripamil) is a fast-acting, intranasally administered calcium-channel blocker, which is being evaluated for the treatment of Paroxysmal Supraventricular Tachycardia.
Lead Product(s): Etripamil,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Cardamyst
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 26, 2024
Lead Product(s) : Etripamil,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil to Treat PSVT
Details : MSP-2017 (etripamil) is a fast-acting, intranasally administered calcium-channel blocker, which is being evaluated for the treatment of Paroxysmal Supraventricular Tachycardia.
Product Name : Cardamyst
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 26, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
34
PharmaCompass offers a list of Etripamil API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Etripamil manufacturer or Etripamil supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Etripamil manufacturer or Etripamil supplier.
PharmaCompass also assists you with knowing the Etripamil API Price utilized in the formulation of products. Etripamil API Price is not always fixed or binding as the Etripamil Price is obtained through a variety of data sources. The Etripamil Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Etripamil manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Etripamil, including repackagers and relabelers. The FDA regulates Etripamil manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Etripamil API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Etripamil manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Etripamil supplier is an individual or a company that provides Etripamil active pharmaceutical ingredient (API) or Etripamil finished formulations upon request. The Etripamil suppliers may include Etripamil API manufacturers, exporters, distributors and traders.
click here to find a list of Etripamil suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Etripamil Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Etripamil GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Etripamil GMP manufacturer or Etripamil GMP API supplier for your needs.
A Etripamil CoA (Certificate of Analysis) is a formal document that attests to Etripamil's compliance with Etripamil specifications and serves as a tool for batch-level quality control.
Etripamil CoA mostly includes findings from lab analyses of a specific batch. For each Etripamil CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Etripamil may be tested according to a variety of international standards, such as European Pharmacopoeia (Etripamil EP), Etripamil JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Etripamil USP).
